Tim Scott actually said...

"I would appreciate you expounding on that because there has been much conversation around the pricing."

"Anything we can do to try to make that process more predictable, to create bright lines, to use better tools to evaluate safety and effectiveness that could bring down the cost."

"I come back to the Cures Act because I think that there is a lot of opportunity for that to be a template for policymaking in this regard."

"I applaud the commitment to patient-focused drug development in PDUFA V."